Drugging the cancer genome and the cancer state

Nieuwe afbeelding.png (2)

Are you interested? Precision genomic medicine is now a reality in the clinic. There are numerous successful examples of ‘drugging the cancer genome’. Come and learn more about this subject from ICR Chief Executive Paul Workman, named one of London’s most influential people, during the Radboud New Frontiers Symposium. Other interesting lectures about the future of cancer imaging, cancer immunology, cancer prevention, and patient participation and their consequences for daily practice on 24-25 November.

Theme of the New Frontiers Symposium is “Cancer research: bridging the gap between biology and daily practice”. Each session of the program has been planned in a way that it is of interest to both molecular life scientists and health scientists as well as to clinicians with a focus on patient care instead of research.

A large panel of internationally renowned scientists that have contributed significantly to these topics will give keynote lectures: Katy Pritchard-Jones (UCL, London), Christoffer Johansen (Danish Cancer Society, Copenhagen), Donald Berry (MD Anderson Cancer Center, Houston), Ignacio Melero (University of Navarra, Pamplona), Per Hall (Karolinska Institute, Stockholm), Rengaswamy Sankaranarayanan (IARC, Lyon), Paul Pharoah (University of Cambridge).

If you are interested in (the future of) cancer you should be there! Please point your colleagues to the symposium and sign in.

More information about the complete program, registration and abstract submission can be found here.


<< back to overview news items